Breakthrough T1D, Formerly JDRF, Statement on FDA Decision Not to Approve Zynquista (sotagliflozin) for Glucose Control in People with Type 1 Diabetes and Chronic Kidney Disease
November 22, 2024
November 22, 2024
NEW YORK, Nov. 22 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, issued the following news release:
Breakthrough T1D, formerly JDRF, is extremely disappointed that the U.S. Food and Drug Administration (FDA) decided not to approve Zynquista (sotagliflozin), manufactured by Lexicon Pharmaceuticals, for use in glucose control in people with type 1 diabetes (T1D) and chronic kidney disease. People with T1D need additional therapies to ma . . .
Breakthrough T1D, formerly JDRF, is extremely disappointed that the U.S. Food and Drug Administration (FDA) decided not to approve Zynquista (sotagliflozin), manufactured by Lexicon Pharmaceuticals, for use in glucose control in people with type 1 diabetes (T1D) and chronic kidney disease. People with T1D need additional therapies to ma . . .